NTRA NT

NTRA Natera, Inc.

Healthcare · Diagnostics & Research

Momentum 10.0 · Strong

322.10

+21.37%

About the company

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

46.1B
-1.62
221.05

52-week range

322
low 149 high 323
Yield Growth Momentum Safety Value Health

Dividend deep dive

Natera, Inc. (NTRA) is an equity instrument with a market capitalization of $38,867,222,2528.0. The company does not currently pay a dividend, as indicated by a null dividend yield and no historical dividend payments in the provided data. Therefore, there is no headline dividend picture, yield versus its 5-year band, or rating available. Both momentum and value scores are not provided in the data.

Dividend history

Natera, Inc. does not have a reported dividend payment history in the provided data. There is no information available regarding a streak of dividend increases, nor are 3-year or 5-year Compound Annual Growth Rates (CAGRs) for dividends provided. The dividend history data itself is empty, indicating an absence of past dividend payments to analyze. The company's payment frequency and specific payment months are also not available.

Dividend safety

The dividend safety cannot be assessed as Natera, Inc. does not currently pay a dividend. Therefore, there is no payout ratio to evaluate.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 19 Jul 2026 · Information, not financial advice.

Price history

271 153 35.1 2021 2022 2023 2024 2025 2026 2020-08 · 63.7 2020-09 · 72.2 2020-10 · 67.3 2020-11 · 88.3 2020-12 · 99.5 2021-01 · 107 2021-02 · 116 2021-03 · 102 2021-04 · 110 2021-05 · 94.1 2021-06 · 114 2021-07 · 115 2021-08 · 118 2021-09 · 111 2021-10 · 115 2021-11 · 91.5 2021-12 · 93.4 2022-01 · 70.7 2022-02 · 65.8 2022-03 · 40.7 2022-04 · 35.1 2022-05 · 36.7 2022-06 · 35.4 2022-07 · 47.0 2022-08 · 49.3 2022-09 · 43.8 2022-10 · 47.0 2022-11 · 41.1 2022-12 · 40.2 2023-01 · 42.9 2023-02 · 48.5 2023-03 · 55.5 2023-04 · 50.7 2023-05 · 47.1 2023-06 · 48.7 2023-07 · 45.2 2023-08 · 58.7 2023-09 · 44.3 2023-10 · 39.5 2023-11 · 56.0 2023-12 · 62.6 2024-01 · 65.9 2024-02 · 86.5 2024-03 · 91.5 2024-04 · 92.9 2024-05 · 107 2024-06 · 108 2024-07 · 102 2024-08 · 118 2024-09 · 127 2024-10 · 121 2024-11 · 168 2024-12 · 158 2025-01 · 177 2025-02 · 156 2025-03 · 141 2025-04 · 151 2025-05 · 158 2025-06 · 169 2025-07 · 134 2025-08 · 168 2025-09 · 161 2025-10 · 199 2025-11 · 239 2025-12 · 229 2026-01 · 231 2026-02 · 208 2026-03 · 200 2026-04 · 206 2026-05 · 223 2026-06 · 271 2026-07 · 271
Price

Dividend profile

Frequency
Growth (TTM)
CAGR 3y

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

13.5%
2.96
2.70
Debt vs cash
Debt Cash
Total debt
240.1M USD
Total cash
1.1B USD
-267.6M USD

Latest reported balance-sheet figures.

Information, not financial advice.

Quantic · Free

Track NTRA and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →